Breaking News

Breaking: Federal Judge Vacates HRSA’s May 17 Letter to Lilly on 340B Contract Pharmacies, Sends Matter Back to Agency

A federal district judge late this afternoon struck down, as arbitrary and capricious, HRSA's finding that Lilly's 340B contract pharmacy policies violate the 340B statute. However, the judge said that manufacturers should not be allowed to unilaterally impose conditions on the location and delivery of 340B drugs and sent the matter back to HRSA.

A federal district judge in Indianapolis late this afternoon set aside and vacated the federal government’s May 17 finding that drug manufacturer Eli Lilly’s denials of 340B ceiling prices when covered entities use contract pharmacies violate the 340B

Read More »

340B Lobbying Intensifies on Capitol Hill and in Federal Agencies

2021 could be the runner up to 2018 in terms of 340B lobbying intensity, as measured by citations on lobbying disclosure forms.

2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.

Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic

Read More »

Both Sides in AstraZeneca’s 340B Contract Pharmacy Case Want a Quick Ruling, but It’s Unclear if They Will Get One

Both sides in AstraZeneca's 340B contract pharmacy lawsuit want an expedited decision, but for very different reasons.

Drug manufacturer Astra Zeneca and the federal government both want a federal district judge in Delaware to rule quickly in the drug company’s lawsuit over the government’s 340B contract pharmacy requirements.

The two sides, however, are miles apart

Read More »

D.C. Federal Judge Picks Up a Fourth 340B Contract Pharmacy Lawsuit

U.S. District Judge Dabney Friedrich is now in charge of four 340B contract pharmacy lawsuits.

U.S. District Judge Dabney Friedrich of the District of Columbia has been assigned to a fourth 340B contract pharmacy lawsuit.

Boehringer Ingelheim’s (BI) lawsuit in defense of its policy of denying hospitals 340B drug discounts when hospitals use

Read More »

Federal Court Decision on Novel Arkansas 340B Contract Pharmacy Law Might Not Come Until 2023

A federal district judge in Little Rock might not rule on Arkansas’s 340B nondiscrimination law might until sometime in 2023.

A federal court ruling on the legality and constitutionality of Arkansas’s 340B nondiscrimination law might not come until sometime in 2023.

U.S. Senior District Judge Billy Roy Wilson on Monday issued an initial scheduling order in the drug

Read More »

HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges

HRSA has ordered Akorn Inc. and BioComp Pharma to repay 340B covered entities for overcharges following audits.

The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.

HRSA updated its fiscal year 2021 audit results on its website last

Read More »

Updates on 340B Administrative Dispute Resolution Lawsuits and ADR Panel Hearings

There were several recent important developments involving HRSA's 340B administrative dispute resolution system. | Credit: "File:Massimo Busacca, Referee, Switzerland (10).jpg" by Steindy (talk) 11:44, 19 June 2011 (UTC) is licensed under CC BY-SA 3.0

The federal government and the two groups that sued it separately to force it to issue long delayed 340B administrative dispute resolution (ADR) regulations agreed last night to keep stays in place in both lawsuits until Jan. 3,

Read More »

Virginia Health Center Joins 340B-Related Antitrust Suit Against Insulin and Diabetes Drug Makers

Central Virginia Health Services has joined an antitrust lawsuit against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

A central Virginia community health center has joined an upstate New York health center’s antitrust lawsuit against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

Central Virginia

Read More »

California Still Plans to Move Medicaid Pharmacy Benefits to Fee-for-Service in January

California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year.

UPDATE Tuesday, Oct. 26, 2021, 5:00 p.m. EDT—We have updated this article to reflect new information from the California Department of Health Care Services (DHCS) about the timeframe for the U.S. Centers for Medicare & Medicaid Services (CMS)

Read More »

News Alert: Boehringer Ingelheim Sues HRSA in Defense of its 340B Contract Pharmacy Policy

Boehringer Ingelheim sued the federal government this afternoon in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

BI is the seventh

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors